1. Fig. 1. GDF15 is up-regulated with obesity, and AAV-GDF15 improves metabolic parameters in DIO mice.
GDF15 is up-regulated with obesity, and AAV-GDF15 improves metabolic parameters in DIO mice. (A) Microarray signal intensity of GDF15 in the liver and fat tissues from C57BL/6 and ob/ob mice (n = 5 to 6). (B) Serum GDF15 concentrations in lean and obese mice (n = 5 to 8), rats (n = 5 to 6), and humans (n = 16). (C) Body weight, average daily food intake 1 month after AAV-hGDF15 injection; glucose, insulin, triglyceride, and cholesterol concentrations 5 months after AAV injection; and serum hGDF15 concentrations 12, 81, and 350 days after AAV injection in male B6D2F1 DIO mice injected with empty vector or AAV-hGDF15 (n = 5 to 15). (D) Fat mass, lean mass, and bone mineral density of 18-month-old male B6D2F1 DIO mice injected with empty vector 12 months after AAV injection, 18-month-old male B6D2F1 DIO mice injected with AAV-hGDF15 12 months after AAV injection, and a group of untreated 12-week-old mice on normal chow (n = 3). *P < 0.05, **P < 0.01, and ***P < versus empty vector by analysis of variance (ANOVA).
Yumei Xiong et al., Sci Transl Med 2017;9:eaan8732
Copyright © 2017 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works